Pharma Journalist -

BioNTech SE  announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel…
Read More...

Purple Biotech Ltd., a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, announced that it has entered into a Research…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer…
Read More...

Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI (encorafenib) in combination with cetuximab…
Read More...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain…
Read More...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd),…
Read More...

Kazia Therapeutics Limited an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of…
Read More...

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics Orion Corporation (“Orion”) and Invenra…
Read More...

ImmunityBio, Inc. announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Ltd.), a global oncology company, to conduct a…
Read More...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced that the European Commission has authorised…
Read More...